



Contents

<i>Preface</i>	<i>v</i>
1. Introduction to Medicinal Chemistry	1–4
1.1 Introduction	1
1.2 Drug Design	3
1.2.1 Discovery and Research	3
1.2.2 Drug Development	3
1.2.3 Regulatory Review and Approval	4
1.2.4 Marketing	4
2. General Principle of Drug Action	5–11
1. Introduction	5
2. Absorption of Drug	5
3. Distribution of Drug	9
4. Protein Binding	10
4.1 Tissue Depots	10
5. Metabolism and Excretion	11
3. Receptors	12–32
1. Introduction	12
2. Drug – Receptor Interaction	14
3. Drug – Receptor Bonds	16
3.1 Covalent Bond	16
3.2 Ionic Bond	16
3.3 Hydrogen Bond	17
3.4 Hydrophobic Interaction	17
3.5 Van der Waals (or) London forces	18
3.6 Charge Transfer Complexes	18
4. Theories of Receptor	18
4.1 Occupation Theory	18
4.2 Rate Theory	20
4.3 The Induced – Fit Theory of Enzyme — Substrate Interaction	21
4.4 Macromolecular Perturbation Theory	21
4.5 Activation – Aggregation Theory	22
4.6 Two State Receptor Model	23

5. Types of Receptors	23
5.1 Channel Linked Receptor or Ligand – Gated ion Channel Receptors	23
5.2 G - Protein Coupled Receptors	24
5.3 Membrane Bound Enzyme Receptors	28
5.4 Nuclear Receptor or Intracellular Receptor	31
5.5 Summary of Receptor Types	32
4. Physicochemical Parameters in Relation to Biological Activity	33–63
1. Introduction	33
2. Physical Properties	33
2.1 Solubility	33
2.2 Partition co-efficient	37
2.3 Ionization and pK _a value	38
2.4 Hydrogen-Bonding	42
2.5 Surface Activity	44
2.6 Complexation	45
2.7 Redox Potential	45
3. Steric Features of Drug	48
3.1 Conformational Isomers	49
3.2 Optical Isomers	51
4. Bioisosterism	54
4.1 Classical Bioisosteres	55
4.2 Non-classical Bioisosteres	59
5. Drug Metabolism	64–110
1. Introduction	64
1.1 Sites of Bio-transformation	64
1.2 Pathways of Drug Metabolism	65
1.3 General Summary of Phase I and Phase II Metabolic Pathway	66
1.4 Enzymes Involved in Drug Metabolism	67
2. Phase I Reactions	70
2.1 Oxidative Reactions	70
2.1.1 Oxidation of Aromatic Carbon Atom	72
2.1.2 Oxidation of Olefins	75
2.1.3 Oxidation at Benzylic Carbon	76
2.1.4 Oxidation of Allylic Carbon	77
2.1.5 Oxidation of Carbon atom to Carbonyl and Imines	78
2.1.6 Oxidation of Aliphatic Carbon atom (Aliphatic hydroxylation)	79
2.1.7 Oxidation of Alicyclic Carbon atom	79
2.1.8 Oxidation of Carbon-Hetero atoms	80

2.1.9 Oxidation Involving C-N system	80
2.1.10 Oxidation of Carbon-Sulfur System	85
2.1.11 Oxidation Involving Carbon-Oxygen System	87
2.1.12 Other Oxidative Bio-transformation	88
2.2 Reduction Reactions	89
2.2.1 Reduction of Aldehyde and Ketone	89
2.2.2 Reduction of Azo and Nitro Compound	90
2.3 Hydrolytic Reactions	90
2.3.1 Hydrolysis of Esters and Amides	90
2.3.2 Hydrolysis of Amide	91
3. Phase II (or) Conjugation Reactions	92
3.1 Glucuronic acid Conjugation	92
3.2 Sulfate Conjugation	95
3.3 Conjugation with α -amino acids	97
3.4 Conjugation with Glutathione	98
3.5 Acetyl conjugation	101
3.6 Methylation	103
4. Factors Affecting Drug Metabolism	105
6. Prodrugs	111–135
1. Introduction	111
2. Prodrug strategy in Drug Design	112
3. Ideal Requirements of Prodrug	114
4. Types of Prodrugs	114
4.1 Carrier Linked Prodrug	114
4.2 Bio-precursor Prodrug	120
5. Applications of Prodrug	121
5.1 Pharmaceutical Applications	121
5.2 Pharmacological Applications	125
7. General Anaesthetics	136–148
1. Introduction	136
2. Mechanism of Action	136
3. Classification	137
3.1 Inhalation Anaesthetics	138
3.2 Intravenous Anaesthetics	144
8. Local Anaesthetics	149–170
1. Introduction	149
2. Mechanism of Action	149

3. Structure Activity Relationship	150
4. Classification	152
4.1 Ester based	153
4.2 Amide based	161
4.3 Amino Ether derivatives	166
4.4 Amino Ketone derivatives	168
4.5 Alcohol derivatives	168
4.6 Miscellaneous	169
9. Sedative and Hypnotics	171–206
1. Introduction	171
2. Classification	171
2.1 Barbiturates	173
2.2 Benzodiazepines	186
2.3 Triazolo-1, 4 - Benzodiazepines	197
2.4 Pyrazolo Pyrimidine	199
2.5 Imidazopyridine	199
2.6 Cyclopyrrolone derivative	200
2.7 Piperidinedione derivatives	200
2.8 Disubstituted Quinazolone derivative	202
2.9 Carbamic acid Ester of Glycol	202
2.10 Carbamic acid Ester of Alcohol	203
2.11 Chloral derivatives	204
2.12 Acetylenic Alcohol	204
2.13 Cyclic Ether	205
2.14 Piperazine derivative	205
2.15 Miscellaneous	206
10. Anticonvulsants	207–222
1. Introduction	207
2. Classification	209
2.1 Barbiturates	210
2.2 Hydantoins	211
2.3 Oxazolidinediones	213
2.4 Succinimides	215
2.5 Imino stilbenes	217
2.6 Benzodiazepines	218
2.7 Newer Antiepileptics	220
2.8 Miscellaneous	221

11. Central Nervous System Stimulant	223–268
1. Introduction	223
2. Analeptics	224
2.1 Introduction	224
3. Methyl Xanthines	226
3.1 Introduction	226
3.2 Mechanism of Action	227
4. Psychomotor Stimulants	233
4.1 Introduction	233
4.2 Cocaine	233
4.3 Central Sympathomimetic Analeptics	234
5. Antidepressant	242
5.1 Introduction	242
5.2 Classification	243
5.2.1 Mono Amine Oxidase Inhibitors (MAOIs)	243
5.2.2 Tricyclic Antidepressant	247
5.2.3 Selective Serotonin Reuptake Inhibitors (SSRIs)	256
5.2.4 Selective Norepinephrine Reuptake Inhibitors (SNRI)	259
5.2.5 Dual Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)	260
5.2.6 Norepinephrine and Dopamine Reuptake Inhibitor (NDRI)	261
5.2.7 Alpha-2 Antagonist plus Serotonin-2 and Serotonin-3 Antagonist	261
5.2.8 Serotonin-2-antagonist and Reuptake Inhibitors (SARIs)	262
5.2.9 Serotonin Reuptake Enhancer	263
6. Psychotomimetic Drugs [Hallucinogenic Drug]	264
6.1 Introduction	264
6.2 Classification	264
6.2.1 Aryl Amino Hallucinogens	265
6.2.2 Dissociate agents	267
6.2.3 Euphorian – Stimulant	267
6.2.4 Depressant – Intoxicant	267
12. Tranquilizers	269–286
1. Introduction	269
2. Classification	269
2.1 Phenothiazines	270
2.2 Benzodiazepines	279
2.3 Fluoro Butyrophenones	280

2.4 Thioxanthenes	283
2.5 Dibenzoxazepines	285
2.6 Benzisoxazole	286
13. Antihistamines	287–326
1. Introduction	287
2. Histamine Release Inhibitors — Mast Cell Stabilizers	289
2.1 Introduction	289
3. Released Histamine Inhibitors (H_1 Antagonist - Antihistamines)	291
3.1 Introduction	291
3.2 Mechanism of Action of Antihistamines	291
3.3 Structure Activity Relationship	291
3.4 Therapeutic Applications of Antihistamines	293
3.5 Classification	293
3.5.1 First Generation H_1 Antagonists	294
3.5.2 Second Generation Antihistamines	315
3.5.3 Topical Antihistamines	319
4. Anti-Secretory Drugs	320
4.1 Introduction	320
4.2 Classification of Antiulcer Drugs	320
4.2.1 H_2 - Receptor Antagonist	320
4.2.2 Proton Pump Inhibitors	324
14. Diuretics	327–359
1. Introduction	327
2. Classification	333
2.1 Mercurial Diuretics	334
2.2 Non-mercurial Diuretics	336
2.2.1 Thiazide and Hydrothiazide Diuretics	336
2.2.2 <i>Carbonic Anhydrase</i> Inhibitors	345
2.2.3 Sulphonamide Diuretics	350
2.2.4 Aldosterone Antagonists	352
2.2.5 High Ceiling or Loop Diuretics	353
2.2.6 Methyl xanthines	357
2.2.7 Pyrazinoyl Guanidine	357
2.2.8 Osmotic Diuretics	358
2.2.9 Miscellaneous	359

15. Analgesics, Antipyretics and Antirheumatics	360–377
1. Introduction	360
2. Classification	360
2.1 Aniline and p-Aminophenol Analogues	361
2.2 Salicylic acid Analogues	363
2.3 Quinoline derivatives	367
2.4 Pyrazolones and Pyrazolidinones	368
2.5 N - Arylanthranilic acid derivatives	373
3. Anti-Rheumatic Agents	375
3.1 Introduction	375
3.2 Classification	375
16. Narcotic Analgesics	376–408
1. Introduction	376
2. Classification	379
2.1 Morphine and its Related Compounds	379
2.2 Morphinan Analogues	393
2.3 Morphan Analogues	395
2.4 4 - Phenyl Piperidine Analogues	396
2.5 Phenyl propylamine Analogues	400
2.6 Miscellaneous	401
3. Narcotic Antagonists	402
4. Antitussives	405
4.1 Introduction	405
4.1.1 Centrally acting Antitussives	405
4.1.2 Peripherally acting Antitussives	405
17. Non-Steroidal Anti-Inflammatory Drugs	409–425
1. Introduction	409
2. Mechanism of Action	409
3. Structure Activity Relationship	411
4. Classification	412
4.1 Heteroaryl acetic acid Analogues	413
4.2 Aryl acetic acid Analogues	416
4.3 Aryl Propionic acid Analogues	419
4.4 Oxicams	422
4.5 Selective COX-2 Inhibitors	423

18. Cholinergic and Anticholinergic Drugs	426–469
1. Introduction	426
1.1 Neurochemistry	427
1.2 Acetylcholine	428
1.2.1 Stereochemistry of Acetylcholine	428
1.2.2 Acetylcholine Receptors	429
2. Cholinomimetic (or) Parasympathomimetic Agents	433
2.1 Introduction	433
2.2 Classification	434
2.2.1 Direct acting Cholinergic Drugs	434
2.2.2 Indirect acting Cholinergic Agonist	439
3. Cholinergic Blocking Agents (or) Antispasmodics	447
3.1 Introduction	447
3.2 Structure Activity Relationship	447
3.3 Therapeutic Uses	448
3.4 Parasympathetic Postganglionic Blocking Agents	449
3.4.1 Classification	449
3.4.1.1 Solanaceous Alkaloids	449
3.4.1.2 Synthetic Cholinergic Blocking Agents	453
4. Ganglionic Blocking Agents	462
4.1 Introduction	462
4.2 Classification	462
5. Neuromuscular Blocking agent	465
5.1 Natural Compounds	465
5.2 Synthetic Compounds	467
19. Adrenergic Drugs	470–516
1. Introduction	470
1.1 Adrenergic Nerve Transmission	470
1.2 Biosynthesis	471
1.3 Metabolism and Distribution of Catecholamines	473
1.4 Adrenergic Receptors	474
1.5 Clinical uses of Adrenergic Agents	476
2. Sympathomimetic Agents	476
2.1 Introduction	476
2.2 Structure Activity Relationship	477

2.3 Classification of Adrenergic Agonists	479
2.3.1 Direct-Acting Sympathomimetics (Agonists)	480
2.3.1.1 Endogenous Catecholamines	480
2.3.1.2 α - Adrenergic Receptor Agonist	483
2.3.1.3 β - Adrenergic Receptor Agonist	490
2.3.1.4 Dual α and β - Adrenergic Receptor Agonist	495
2.3.2 Indirect - Acting Sympathomimetics	496
2.3.3 Sympathomimetic with Mixed Mechanism of Action	498
3. Sympatholytic (or) Adreno Receptor Blocking Agents	500
3.1 α - Adrenergic Blocking Agents	500
3.1.1 Ergot Alkaloids	500
3.1.2 Quinazolines	501
3.1.3 Imidazolines	505
3.1.4 β - Halo alkyl amines	506
4. β - Adrenergic Blocking Agents	508
4.1 Introduction	508
4.2 Structure Activity Relationship	508
4.3 Classification	509
4.3.1 Aryloxy Propyl Amines	510
4.3.2 Aryl Ethanol Amine derivative	515
5. β - Blockers with α_1 - Receptor Antagonist Activity	515
20. Prostaglandins	517–538
1. Introduction	517
2. Nomenclature	518
2.1 Nature of Cyclopentane Ring	519
2.2 Nature of the Side Chain	520
3. Biosynthesis	521
3.1 Cyclooxygenase pathway	521
3.2 Lipoxygenase pathway	523
4. Pharmacological Activities	525
5. Structure Activity Relationship	531
6. Eicosanoids Approved for Clinical Use	534
7. Prostaglandins for Ophthalmic Use	536
<i>Index</i>	539–546